Human Genome Sciences, Inc.

Other

Smithkline Beecham Corporation

The Johns Hopkins University

Transgene S.a.

The Institute for Genomic Res.

Mark D Adams

Craig A Rosen

Haodong Li

Ewen F Kirkness

Claire M Fraser

Steven M Ruben

Henrik S Olsen

Robert D Fleischmann

Gregg A Hastings

Lisa M Fitzgerald

Judith A Blake

Fred H Drake

Norman H Lee

Rebecca A Fuldner

Maxine Gowan

Ying-Fei Wei

Timothy A Coleman

J Craig Venter

Hamilton O Smith

Owen White

William A Haseltine

Ralph Froman Alderson

Yuling Li

David M Parmelee

Jian Ni

Reiner L Gentz

Jun Zhang

Yi Li

Jeannine D Gocayne

Edward Robert Appelbaum

Brent L Kreider

John Richard White

Donna Mendrick

Pablo Jimenez

Vikram P Patel

Michael Antonaccio

John M Greene

Paul S Meissner

Daniel R Soppet

Liang Cao

Daniel P Bednarik

Steve Ruben

Solange H L Gentz

Solange Hanschke Lima

Ying Fei-Wei

John M White

Bert Vogelstein

Kenneth W Kinzler

Nicholas C Nicolaides

Nickolas Papadopoulos

Christine Marie Debouck

Julie A Rood

Edward B Applebaum

Clyde A Hutchison, Iii

Henrick S Olsen

Solange H Gentz

Valérie Calenda

Virginie Fataccioli

John M Green

Owen R White

Maxine Gowen

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1 (CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1(CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)

The present invention relates to human Corpuscles of Stannius polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antagonists against such polypeptides. Human Corpuscles of Stannius protein inhibits calcium uptake and reduces renal excretion of phosphate. Also provided is a diagnostic assay to detect mutations in the nucleic acid sequence encoding the polypeptide and for altered concentrations of the polypeptide in a sample derived from a host.

Methods for detecting Corpuscles of Stannius protein stanniocalcin

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

Human osteoclast derived cathepsin

Human Ck&#x3b2;-9 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Ck&#x3b2;-9 polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays are also disclosed which detect the presence of mutations in the Ck&#x3b2;-9 coding sequence and over-expression of the Ck&#x3b2;-9 protein.

Human chemokine &#x3b2;-9 viral vectors

Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Human Ck&#x3b2;-10 polynucleotides

Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Antibodies to MCP-4

Antibodies to human chemokine beta-9

Antibodies to monocyte-colony inhibitory factor (M-CIF)

The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Connective tissue growth factor-2

Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Human chemokine beta-10 mutant polypeptides

Antibodies to chemokine &#x3b2;-4

A human HPRT-2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of nephrolithiasis, anemia, precocious gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria. Antagonists against such polypeptides and their use as a therapeutic to treat disorders associated with excessive purine synthesis are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequences encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Human hypoxanthine-(guanine) phosphoribosyl transferase-2

The present invention provides the sequencing of the entire genome ofRd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of thegenome.

Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof

Growing community of inventors

North Potomac, MD, United States of America

Mark D Adams